Tags

Type your tag names separated by a space and hit enter

Clinical experience with a triphasic oral contraceptive ('Trinordiol') in young women.
Curr Med Res Opin. 1983; 8(6):395-404.CM

Abstract

Seven hundred and fifty cycles of treatment with a new triphasic oral contraceptive (WL-49(50). 'Trinordiol') containing the lowest quantity of steroids of all available preparations were evaluated in 75 healthy young women (mean age 19.6 years), 70% of whom had regular, normal cycles. Sixty-five percent had not used contraception before; the others had previously been on combined or progestagen-only oral contraceptives or had an IUD. The mean length of treatment with the triphasic preparation was 10 cycles. No pregnancy was recorded during the 750 cycles of treatment. Fifteen (20%) women dropped out of the study for medical reasons, essentially breast tenderness, weight increase, spotting and nausea, in decreasing order of frequency. Mastalgia was present in 21% of the women (8.9% of the cycles) during triphasic oral contraception, but this symptom disappeared in more than half of the cases within 3 months of continued use. Other side-effects were less frequent: vaginal discharge (4.4% of the cycles), nausea (3.7%), abdominal and leg cramps (2.8%), headaches (3.2%) and weight increase (3%). Spotting and breakthrough bleeding were reported during only 1.9% of the cycles, a remarkably low frequency. No absence of withdrawal bleeding was noted. Weight and blood pressure changes were minimal and never reached statistical significance. Hypertension developed during triphasic medication in 1 predisposed individual. Complaints of oestrogen-related symptoms such as breast tenderness and digestive disorders were probably due to the reduced progestagen content of the preparation compared with combined low fixed daily dose oral contraceptives. However, no increases in dysmenorrhoea and/or premenstrual tension were noted. It is concluded that the triphasic preparation provides effective contraception with excellent cycle control and minimal side-effects, which should help to increase the acceptability of low-dose combined oral contraceptives.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

6406157

Citation

Gaspard, U J., et al. "Clinical Experience With a Triphasic Oral Contraceptive ('Trinordiol') in Young Women." Current Medical Research and Opinion, vol. 8, no. 6, 1983, pp. 395-404.
Gaspard UJ, Deville JL, Dubois M. Clinical experience with a triphasic oral contraceptive ('Trinordiol') in young women. Curr Med Res Opin. 1983;8(6):395-404.
Gaspard, U. J., Deville, J. L., & Dubois, M. (1983). Clinical experience with a triphasic oral contraceptive ('Trinordiol') in young women. Current Medical Research and Opinion, 8(6), 395-404.
Gaspard UJ, Deville JL, Dubois M. Clinical Experience With a Triphasic Oral Contraceptive ('Trinordiol') in Young Women. Curr Med Res Opin. 1983;8(6):395-404. PubMed PMID: 6406157.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical experience with a triphasic oral contraceptive ('Trinordiol') in young women. AU - Gaspard,U J, AU - Deville,J L, AU - Dubois,M, PY - 1983/1/1/pubmed PY - 1983/1/1/medline PY - 1983/1/1/entrez KW - Belgium KW - Bleeding KW - Body Weight KW - Contraception KW - Contraception Failure--statistics KW - Contraceptive Agents KW - Contraceptive Agents, Estrogen KW - Contraceptive Agents, Female KW - Contraceptive Agents, Progestin KW - Contraceptive Effectiveness KW - Contraceptive Methods KW - Contraceptive Methods--side effects KW - Contraceptive Usage KW - Developed Countries KW - Diseases KW - Ethinyl Estradiol KW - Europe KW - Evaluation KW - Family Planning KW - Gastrointestinal Effects KW - Levonorgestrel KW - Menstrual Cycle KW - Menstruation KW - Menstruation Disorders KW - Metrorrhagia KW - Oral Contraceptives, Combined KW - Oral Contraceptives--side effects KW - Reproduction KW - Reproductive Control Agents KW - Signs And Symptoms KW - Use-effectiveness KW - Western Europe SP - 395 EP - 404 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 8 IS - 6 N2 - Seven hundred and fifty cycles of treatment with a new triphasic oral contraceptive (WL-49(50). 'Trinordiol') containing the lowest quantity of steroids of all available preparations were evaluated in 75 healthy young women (mean age 19.6 years), 70% of whom had regular, normal cycles. Sixty-five percent had not used contraception before; the others had previously been on combined or progestagen-only oral contraceptives or had an IUD. The mean length of treatment with the triphasic preparation was 10 cycles. No pregnancy was recorded during the 750 cycles of treatment. Fifteen (20%) women dropped out of the study for medical reasons, essentially breast tenderness, weight increase, spotting and nausea, in decreasing order of frequency. Mastalgia was present in 21% of the women (8.9% of the cycles) during triphasic oral contraception, but this symptom disappeared in more than half of the cases within 3 months of continued use. Other side-effects were less frequent: vaginal discharge (4.4% of the cycles), nausea (3.7%), abdominal and leg cramps (2.8%), headaches (3.2%) and weight increase (3%). Spotting and breakthrough bleeding were reported during only 1.9% of the cycles, a remarkably low frequency. No absence of withdrawal bleeding was noted. Weight and blood pressure changes were minimal and never reached statistical significance. Hypertension developed during triphasic medication in 1 predisposed individual. Complaints of oestrogen-related symptoms such as breast tenderness and digestive disorders were probably due to the reduced progestagen content of the preparation compared with combined low fixed daily dose oral contraceptives. However, no increases in dysmenorrhoea and/or premenstrual tension were noted. It is concluded that the triphasic preparation provides effective contraception with excellent cycle control and minimal side-effects, which should help to increase the acceptability of low-dose combined oral contraceptives. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/6406157/Clinical_experience_with_a_triphasic_oral_contraceptive__'Trinordiol'__in_young_women_ L2 - https://www.tandfonline.com/doi/full/10.1185/03007998309111745 DB - PRIME DP - Unbound Medicine ER -